<?xml version='1.0' encoding='utf-8'?>
<document id="29118985"><sentence text="Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy."><entity charOffset="66-76" id="DDI-PubMed.29118985.s1.e0" text="atazanavir" /><entity charOffset="77-86" id="DDI-PubMed.29118985.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.29118985.s1.e0" e2="DDI-PubMed.29118985.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s1.e0" e2="DDI-PubMed.29118985.s1.e1" /></sentence><sentence text="An 11-year-old male with perinatally acquired human immune deficiency virus (HIV) infection on antiretroviral regimen, which included abacavir plus lamivudine (Epzicom), didanosine, ritonavir and atazanavir presented with bilateral axillary striae, increased appetite, fatigue, facial swelling and acute weight gain"><entity charOffset="134-142" id="DDI-PubMed.29118985.s2.e0" text="abacavir" /><entity charOffset="148-158" id="DDI-PubMed.29118985.s2.e1" text="lamivudine" /><entity charOffset="160-167" id="DDI-PubMed.29118985.s2.e2" text="Epzicom" /><entity charOffset="170-180" id="DDI-PubMed.29118985.s2.e3" text="didanosine" /><entity charOffset="182-191" id="DDI-PubMed.29118985.s2.e4" text="ritonavir" /><entity charOffset="196-206" id="DDI-PubMed.29118985.s2.e5" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e0" e2="DDI-PubMed.29118985.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e0" e2="DDI-PubMed.29118985.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e0" e2="DDI-PubMed.29118985.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e0" e2="DDI-PubMed.29118985.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e0" e2="DDI-PubMed.29118985.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e0" e2="DDI-PubMed.29118985.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e1" e2="DDI-PubMed.29118985.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e1" e2="DDI-PubMed.29118985.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e1" e2="DDI-PubMed.29118985.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e1" e2="DDI-PubMed.29118985.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e1" e2="DDI-PubMed.29118985.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e2" e2="DDI-PubMed.29118985.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e2" e2="DDI-PubMed.29118985.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e2" e2="DDI-PubMed.29118985.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e2" e2="DDI-PubMed.29118985.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e3" e2="DDI-PubMed.29118985.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e3" e2="DDI-PubMed.29118985.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e3" e2="DDI-PubMed.29118985.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e4" e2="DDI-PubMed.29118985.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29118985.s2.e4" e2="DDI-PubMed.29118985.s2.e5" /></sentence><sentence text=" Two months prior to presentation, the patient had received a diagnostic and therapeutic intra-articular triamcinolone injection in the knee for pain relief and subsequently became progressively swollen in the face, developed striae bilaterally at the axillae, experienced increased appetite, fatigue and an 8 pound weight gain"><entity charOffset="105-118" id="DDI-PubMed.29118985.s3.e0" text="triamcinolone" /></sentence><sentence text=" During the endocrine workup, suspicion for adrenal insufficiency prompted 24-h urine collection for free cortisol, which was found to be undetectable (below LLQ of 1"><entity charOffset="106-114" id="DDI-PubMed.29118985.s4.e0" text="cortisol" /></sentence><sentence text="0 µg/L)" /><sentence text=" This prompted further evaluation of the hypothalamic-pituitary axis (HPA) by standard dose adrenocorticotropic hormone (ACTH) stimulation test" /><sentence text=" A 250 µg cosyntropin stimulation test was performed and confirmed HPA axis suppression" /><sentence text=" Baseline cortisol level was &lt;1 µg/dL and stimulated cortisol level at 30 min was 3"><entity charOffset="10-18" id="DDI-PubMed.29118985.s8.e0" text="cortisol" /><entity charOffset="53-61" id="DDI-PubMed.29118985.s8.e1" text="cortisol" /><pair ddi="false" e1="DDI-PubMed.29118985.s8.e0" e2="DDI-PubMed.29118985.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s8.e0" e2="DDI-PubMed.29118985.s8.e1" /></sentence><sentence text="8 µg/dL" /><sentence text=" The patient was diagnosed with iatrogenic Cushing syndrome and suppression of HPA axis secondary to the drug interaction between ritonavir (RTV) and intra-articular triamcinolone injection"><entity charOffset="130-139" id="DDI-PubMed.29118985.s10.e0" text="ritonavir" /><entity charOffset="166-179" id="DDI-PubMed.29118985.s10.e1" text="triamcinolone" /><pair ddi="false" e1="DDI-PubMed.29118985.s10.e0" e2="DDI-PubMed.29118985.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s10.e0" e2="DDI-PubMed.29118985.s10.e1" /></sentence><sentence text=" Following endocrine evaluation and workup, the patient was admitted for planned orthopaedic procedure including elective left hamstring lengthening, distal femoral osteotomy and patellar tendon advancement" /><sentence text=" Taking into consideration the diagnosis of iatrogenic Cushing syndrome, at the start of the surgical procedure, 100 mg IV stress dose of hydrocortisone followed by 50 mg hydrocortisone every 8 h for 24 h was administered"><entity charOffset="138-152" id="DDI-PubMed.29118985.s12.e0" text="hydrocortisone" /><entity charOffset="171-185" id="DDI-PubMed.29118985.s12.e1" text="hydrocortisone" /><pair ddi="false" e1="DDI-PubMed.29118985.s12.e0" e2="DDI-PubMed.29118985.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s12.e0" e2="DDI-PubMed.29118985.s12.e1" /></sentence><sentence text=" Stress dosing was discontinued 24 h after the procedure" /><sentence text=" Throughout the hospitalization and upon discharge, the patient continued his ART" /><sentence text=" From initial presentation, patient has remained clinically stable throughout surgery and postoperative period" /><sentence text="" /><sentence text="Drug-drug interaction between ritonavir and triamcinolone can cause Cushing syndrome"><entity charOffset="30-39" id="DDI-PubMed.29118985.s17.e0" text="ritonavir" /><entity charOffset="44-57" id="DDI-PubMed.29118985.s17.e1" text="triamcinolone" /><pair ddi="false" e1="DDI-PubMed.29118985.s17.e0" e2="DDI-PubMed.29118985.s17.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s17.e0" e2="DDI-PubMed.29118985.s17.e1" /></sentence><sentence text="Although triamcinolone has a half-life of 3 h, an intra-articular injection may be systematically absorbed for 3 weeks after injection, and adrenal suppression may last as long as 30 days"><entity charOffset="9-22" id="DDI-PubMed.29118985.s18.e0" text="triamcinolone" /></sentence><sentence text="Co-administration of ritonavir and corticosteroids may result in an increase of plasma levels of corticosteroids levels, as they are both eliminated by CYP3A metabolism, and this interaction has the potential to prolong the half-life of triamcinolone several fold"><entity charOffset="21-30" id="DDI-PubMed.29118985.s19.e0" text="ritonavir" /><entity charOffset="35-50" id="DDI-PubMed.29118985.s19.e1" text="corticosteroids" /><entity charOffset="97-112" id="DDI-PubMed.29118985.s19.e2" text="corticosteroids" /><entity charOffset="237-250" id="DDI-PubMed.29118985.s19.e3" text="triamcinolone" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e0" e2="DDI-PubMed.29118985.s19.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e0" e2="DDI-PubMed.29118985.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e0" e2="DDI-PubMed.29118985.s19.e2" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e0" e2="DDI-PubMed.29118985.s19.e3" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e1" e2="DDI-PubMed.29118985.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e1" e2="DDI-PubMed.29118985.s19.e2" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e1" e2="DDI-PubMed.29118985.s19.e3" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e2" e2="DDI-PubMed.29118985.s19.e2" /><pair ddi="false" e1="DDI-PubMed.29118985.s19.e2" e2="DDI-PubMed.29118985.s19.e3" /></sentence><sentence text="No specific guidelines are available for the management of iatrogenic Cushing syndrome secondary to ritonavir and corticosteroids"><entity charOffset="100-109" id="DDI-PubMed.29118985.s20.e0" text="ritonavir" /><entity charOffset="114-129" id="DDI-PubMed.29118985.s20.e1" text="corticosteroids" /><pair ddi="false" e1="DDI-PubMed.29118985.s20.e0" e2="DDI-PubMed.29118985.s20.e0" /><pair ddi="false" e1="DDI-PubMed.29118985.s20.e0" e2="DDI-PubMed.29118985.s20.e1" /></sentence><sentence text="One treatment option includes replacing ritonavir with a non-protease inhibitor-based regimen"><entity charOffset="40-49" id="DDI-PubMed.29118985.s21.e0" text="ritonavir" /></sentence><sentence text="Initiating hydrocortisone replacement therapy to prevent an adrenal crisis is also an alternate option"><entity charOffset="11-25" id="DDI-PubMed.29118985.s22.e0" text="hydrocortisone" /></sentence><sentence text="" /></document>